Cargando…

Targeting REV7 effectively reverses 5-FU and oxaliplatin resistance in colorectal cancer

BACKGROUND: Despite an enormous research effort, patients diagnosed with advanced colorectal cancer (CRC) still have low prognosis after surgical resection and chemotherapy. The major obstacle for CRC treatment is chemoresistance to front line anti-cancer drugs, such as 5-fluorouracil (5-FU) and oxa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Xianjun, Hou, Wenhou, Liu, Xin, Chai, Jie, Guo, Hongliang, Yu, Jinming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Primary Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7713438/ https://www.ncbi.nlm.nih.gov/pubmed/33292253 http://dx.doi.org/10.1186/s12935-020-01668-z

Ejemplares similares

Long noncoding RNA CRART16 confers 5-FU resistance in colorectal cancer cells by sponging miR-193b-5p
por: Wang, Jingui, et al.
Publicado: (2021)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial
por: Madi, A, et al.
Publicado: (2012)

Large tumor suppressor kinase 2 overexpression attenuates 5-FU-resistance in colorectal cancer via activating the JNK-MIEF1-mitochondrial division pathway
por: Yao, Weilong, et al.
Publicado: (2019)

Inhibition of CDK1 Reverses the Resistance of 5-Fu in Colorectal Cancer
por: Zhu, Yiping, et al.
Publicado: (2020)

Activated gastric cancer-associated fibroblasts contribute to the malignant phenotype and 5-FU resistance via paracrine action in gastric cancer
por: Ma, Yongchen, et al.
Publicado: (2018)

Decytabine enhances cytotoxicity induced by oxaliplatin and 5-fluorouracil in the colorectal cancer cell line Colo-205
por: Flis, Sylwia, et al.
Publicado: (2009)

Carcinoma-associated fibroblasts affect sensitivity to oxaliplatin and 5FU in colorectal cancer cells
por: Gonçalves-Ribeiro, Samuel, et al.
Publicado: (2016)

CircFBXL5 promotes the 5-FU resistance of breast cancer via modulating miR-216b/HMGA2 axis
por: Zhu, Mingzhi, et al.
Publicado: (2021)

Combinational inhibition of EGFR and YAP reverses 5-Fu resistance in colorectal cancer
por: Huang, Changhao, et al.
Publicado: (2020)

Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) ± folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients
por: Bensmaïne, M A, et al.
Publicado: (2001)

Reversal effects of nomegestrol acetate on multidrug resistance in adriamycin-resistant MCF7 breast cancer cell line
por: Li, Jie, et al.
Publicado: (2001)

XPF–ERCC1 Blocker Improves the Therapeutic Efficacy of 5-FU- and Oxaliplatin-Based Chemoradiotherapy in Colorectal Cancer
por: Huang, Ming-Yii, et al.
Publicado: (2023)

Tumor-associated macrophages modulate resistance to oxaliplatin via inducing autophagy in hepatocellular carcinoma
por: Fu, Xiu-Tao, et al.
Publicado: (2019)

Long non-coding RNA MALAT1 regulates oxaliplatin-resistance via miR-324-3p/ADAM17 axis in colorectal cancer cells
por: Fan, Changru, et al.
Publicado: (2020)

Overexpressed GATA3 enhances the sensitivity of colorectal cancer cells to oxaliplatin through regulating MiR-29b
por: Wang, Wei, et al.
Publicado: (2020)

5FU/Oxaliplatin-Induced Jagged1 Cleavage Counteracts Apoptosis Induction in Colorectal Cancer: A Novel Mechanism of Intrinsic Drug Resistance
por: Pelullo, Maria, et al.
Publicado: (2022)

Lactate induces aberration in the miR-30a–DBF4 axis to promote the development of gastric cancer and weakens the sensitivity to 5-Fu
por: Wang, Tengkai, et al.
Publicado: (2021)

The role of GLI1 for 5-Fu resistance in colorectal cancer
por: Zhang, Lining, et al.
Publicado: (2017)

Aspirin suppresses chemoresistance and enhances antitumor activity of 5-Fu in 5-Fu-resistant colorectal cancer by abolishing 5-Fu-induced NF-κB activation
por: Fu, Jinbo, et al.
Publicado: (2019)

A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer
por: Stoehlmacher, J, et al.
Publicado: (2004)

Kaempferol Can Reverse the 5-Fu Resistance of Colorectal Cancer Cells by Inhibiting PKM2-Mediated Glycolysis
por: Wu, Haili, et al.
Publicado: (2022)

Silencing of ETS1 reverses adriamycin resistance in MCF-7/ADR cells via downregulation of MDR1
por: Wei, Jinrong, et al.
Publicado: (2014)

Translationally controlled tumour protein TCTP is induced early in human colorectal tumours and contributes to the resistance of HCT116 colon cancer cells to 5-FU and oxaliplatin
por: Bommer, Ulrich-Axel, et al.
Publicado: (2017)

Epigenetic regulation of osteopontin splicing isoform c defines its role as a microenvironmental factor to promote the survival of colon cancer cells from 5-FU treatment
por: Chang, Siyuan, et al.
Publicado: (2020)

Inhibition of PI3K increases oxaliplatin sensitivity in cholangiocarcinoma cells
por: Leelawat, Kawin, et al.
Publicado: (2009)

Decreased FANCJ caused by 5FU contributes to the increased sensitivity to oxaliplatin in gastric cancer cells
por: Mori, Ryutaro, et al.
Publicado: (2012)

Mechanism of acquired 5FU resistance and strategy for overcoming 5FU resistance focusing on 5FU metabolism in colon cancer cell lines
por: Suetsugu, Tomonari, et al.
Publicado: (2021)

LINC00152 upregulates ZEB1 expression and enhances epithelial-mesenchymal transition and oxaliplatin resistance in esophageal cancer by interacting with EZH2
por: Zhang, Shuyao, et al.
Publicado: (2020)

Gambogic acid reverses oxaliplatin resistance in colorectal cancer by increasing intracellular platinum levels
por: Wang, Qiang, et al.
Publicado: (2018)

A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma
por: Correale, P, et al.
Publicado: (2004)

MiR-29b reverses oxaliplatin-resistance in colorectal cancer by targeting SIRT1
por: Liu, Hui, et al.
Publicado: (2018)

The effect on the small bowel of 5-FU and oxaliplatin in combination with radiation using a microcolony survival assay
por: Gunnlaugsson, Adalsteinn, et al.
Publicado: (2009)

A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma
por: Singhal, Ruchi, et al.
Publicado: (2023)

Reversal Effect of Dihydromyricetin on Multiple Drug Resistance in SGC7901/5-FU Cells
por: Wu, Mingcai, et al.
Publicado: (2020)

LncRNA LBX2-AS1 promotes colorectal cancer progression and 5-fluorouracil resistance
por: Ma, Yu-Nan, et al.
Publicado: (2021)

Cell-cycle synchronization reverses Taxol resistance of human ovarian cancer cell lines
por: Wang, Xueqing, et al.
Publicado: (2013)

Wnt pathway is involved in 5-FU drug resistance of colorectal cancer cells
por: He, Lingfeng, et al.
Publicado: (2018)

Overexpression of sortilin is associated with 5‐FU resistance and poor prognosis in colorectal cancer
por: Blondy, Sabrina, et al.
Publicado: (2020)

Prospective clinical study of capecitabine plus oxaliplatin concurrent chemoradiotherapy after radical resection of rectal cancer
por: Chen, Wanghua, et al.
Publicado: (2018)

Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer
por: Folprecht, Gunnar, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_pgr9allrt1egcb729a5mrnej0g